Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Betamethasone Sodium Phosphate Injectable Suspension Generic Name & Formulations
Legal Class
Rx
General Description
Betamethasone sodium phosphate 3mg/mL; for IM, intra-articular or intralesional inj.
Pharmacological Class
Glucocorticoid.
How Supplied
Contact supplier.
Manufacturer
Betamethasone Sodium Phosphate Injectable Suspension Indications
Indications
Steroid-responsive disorders when oral therapy not feasible.
Betamethasone Sodium Phosphate Injectable Suspension Dosage and Administration
Adult
See literature. Individualize. Titrate to lowest effective dose. Usual range: 0.25–9mg/day.
Children
See literature. Individualize. Titrate to lowest effective dose. Initially 0.02–0.3mg/kg/day in 3 or 4 divided doses.
Betamethasone Sodium Phosphate Injectable Suspension Contraindications
Contraindications
IM inj with idiopathic thrombocytopenic purpura.
Betamethasone Sodium Phosphate Injectable Suspension Boxed Warnings
Not Applicable
Betamethasone Sodium Phosphate Injectable Suspension Warnings/Precautions
Warnings/Precautions
Avoid IV administration. Not for treating traumatic brain injury or optic neuritis. Concomitant systemic fungal infections, active ocular herpes simplex, cerebral malaria, live vaccines: not recommended. Latent or active amebiasis. Strongyloides infection. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. CHF. Recent MI. Hypertension. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Cirrhosis. Unstable or infected joints. Postmenopausal women (osteoporosis risk). Supplement with additional steroids in physiologic stress. Emotional instability. Psychotic tendencies. Myasthenia gravis. Avoid abrupt cessation. Monitor thyroid, weight, growth, fluid, electrolyte balance and intraocular pressure (w. therapy >6weeks). Pregnancy (Cat.C). Nursing mothers.
Betamethasone Sodium Phosphate Injectable Suspension Pharmacokinetics
See Literature
Betamethasone Sodium Phosphate Injectable Suspension Interactions
Interactions
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin). May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (monitor), isoniazid, other CYP3A4 substrates (eg, indinavir, erythromycin). Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. May suppress reactions to skin tests.
Betamethasone Sodium Phosphate Injectable Suspension Adverse Reactions
Adverse Reactions
HPA axis suppression, masks infection, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate and glucose intolerance, inj site reactions; Kaposi's sarcoma, anaphylactoid reactions.
Betamethasone Sodium Phosphate Injectable Suspension Clinical Trials
See Literature
Betamethasone Sodium Phosphate Injectable Suspension Note
Notes
Formerly known under the brand name Celestone.
Betamethasone Sodium Phosphate Injectable Suspension Patient Counseling
See Literature
